Introduction: Little is known regarding age-
Conclusion:
No differences in risk of acute kidney injury were identified between young, older, and very elderly adults when adjusting for other risk factors. Further research is required to identify strategies to optimize the safety of vancomycin in the aging population.
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INTRODUCTION
Vancomycin has long been the workhorse agent for management of infections due to methicillin-resistant Staphylococcus aureus (MRSA); however, its clinical use is limited by nephrotoxicity [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . While older data suggested that nephrotoxicity was initially associated with impurities in original formulations [1, 11] , newer data suggest that nephrotoxicity is associated with risk factors, including patient-specific risk factors [8, 9] , concurrent nephrotoxins [5] [6] [7] 10] and greater vancomycin exposures [2, 3] . Risk factor identification has greatly improved the ability of clinicians to determine which patients are at high risk for nephrotoxicity.
Despite improvements in the literature and practice, there are still limited data on renal safety of vancomycin in the very elderly (age C 80 years old). In 2002, the United Nations deemed the very elderly to be the fastest growing age group worldwide [12] . As of 2010, in the United States, when a person survives up to age 80, they are expected to live an additional 9.1 years [13] . This increased time at risk for infectious diseases, coupled with an increased prevalence of MRSA infections [14] , establishes a great need for information on the safety of vancomycin in these patients.
Previous investigations have provided valuable insight into age-related differences in risk of nephrotoxicity with vancomycin use. Twenty years ago, Vance-Bryan et al. [7] conducted a retrospective cohort study examining the comparative incidence of nephrotoxicity in the elderly (age C 60 years) and young (age\60 years). This study observed an increase in nephrotoxicity in the elderly population; however, this difference was thought to be due to an unequal distribution of other risk factors, like use of loop diuretics [7] . 
MATERIALS AND METHODS

Study Design
This was an institutional review boardapproved, retrospective, matched cohort study at an urban, tertiary care teaching hospital serving a wide variety of medical and surgical specialties. All procedures followed were in Patients were excluded if they had concurrent acute kidney injury prior to initiation of vancomycin (defined as an increase in serum creatinine of 0.3 mg/dL or 50% within 48 h prior to starting vancomycin, or if urine output was \0.5 mL/kg/h for at least 6 h immediately before the initiation of vancomycin), were pregnant, or had an absolute neutrophil count \1,000 cells/mm 3 .
Patients were categorized by age as young monitoring [15] . The primary outcome of interest was nephrotoxicity, defined as an abrupt (within 48 h) increase in serum creatinine of 0.5 mg/dL or 50% above baseline for at least two consecutive measurements [15] .
Secondary outcomes included Acute Kidney Injury Network (AKIN)-modified definition of nephrotoxicity [8] , defined as an increase in serum creatinine of 0.3 mg/dL, a decrease in creatinine clearance of at least 50% or a decrease in urine output to \0.5 mL/kg/h for at least 6 h.
Data Analysis
Descriptive statistics were used to characterize the cohort with respect to patient demographics, treatment characteristics and outcomes. Categorical data were described as proportions, and continuous data were described as means and standard deviations or medians an interquartile ranges, as appropriate. 
RESULTS
Data were obtained for 132 patients meeting inclusion criteria. There were 44 patients in each stratum. Baseline characteristics (Table 1) were similar between groups, with limited exceptions other than age-related differences.
The most common indications for vancomycin treatment were lower respiratory tract, 
There were seven episodes of nephrotoxicity and 44 episodes of acute kidney injury within the cohort. The incidence of nephrotoxicity was 2.3%, 9.1% and 4.5% in the young, older adult and very elderly groups, respectively (p = 0.35, Fig. 1 ). The incidence of acute kidney injury was 34.1%, 34.1% and 31.8% in the young, older adults and very elderly groups, respectively (p = 0.97, Fig. 1 ). Relevant predictors for acute kidney injury, including all variables with p\0.2 in bivariate comparison, are listed in Table 2 . Since there were only seven episodes of nephrotoxicity, only acute kidney injury was explored in the multivariable analysis.
In the logistic regression model, age was entered into the model using the young group as the reference. Based on the pre-specified criteria for model entry and removal, age, lower respiratory tract infection, length of therapy and presence of at least two different risk factors at baseline were included in the final model. Age was not identified as a significant predictor. Adjusting for the presence of more than one baseline risk factor, both lower respiratory tract infection and longer duration of therapy were significant predictors for acute kidney injury.
DISCUSSION
In the era of the 2009 consensus vancomycin guidelines, no independent association between acute kidney injury and advanced age was found in this matched cohort. These findings are similar to work predating these consensus recommendations [7] . Therefore, clinicians
should not routinely use age alone to assess the risk of nephrotoxicity in patients receiving vancomycin. Factors that were found to be associated with acute kidney injury in our study included lower respiratory tract infection and longer duration of therapy, which are also consistent with more recent observational studies [3, 9] . Importantly, the multivariable analysis of this study was based on the secondary endpoint of AKIN-defined nephrotoxicity. The AKIN method of identifying nephrotoxicity has been shown to be more sensitive than the traditional definition of nephrotoxicity [15] , and also explains the higher incidence of acute kidney injury identified in this cohort.
There are several potential explanations for the finding that lower respiratory tract infection was associated with nephrotoxicity. Recent guidelines recommend that due to poor lung penetration of vancomycin [17] , a target trough of 15-20 mg/L is utilized for these infections [15, 18, 19] . This target trough has also been associated with increased incidence of nephrotoxicity [3, 5, 6, 9] . In the present study, targeting a trough concentration of 15-20 mg/L was associated with nephrotoxicity in bivariate analysis; because of shown in experimental models to increase the risk of acute kidney injury [20] ; however, septic shock, as evidenced by use of vasopressors, was not common in this cohort. This study is not without limitations. As with any retrospective study, causality cannot be proven, and data are subject to observer biases at the time of documentation. There is also the possibility that measured and unmeasured confounders influenced outcome. The matched cohort design with multivariable analysis may have reduced this effect. This is the first matched study to specifically examine the relationship between age and acute kidney injury during vancomycin therapy. These data must be considered carefully. Although a Fig. 1 Incidence of nephrotoxicity in each age group. AKI acute kidney injury, NT nephrotoxicity 
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